No Data
Hybio Pharmaceutical (300199.SZ): Liraglutide injection has obtained FDA approval certificate from the USA.
Gelonghui reported on December 24 that Hybio Pharmaceutical (300199.SZ) announced that on December 23, 2024, Shenzhen Hybio Pharmaceutical Co., Ltd. received notification from the USA Food and Drug Administration (referred to as "FDA") that the New Drug Abbreviated Application (referred to as "ANDA") for liraglutide injection filed jointly by Hybio Pharmaceutical and Hikma Pharmaceuticals USA, Inc. (referred to as "Hikma") has been approved. Liraglutide (liraglutide-1) is human glucagon-like peptide 1.
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Shares Climb 34% But Its Business Is Yet to Catch Up
Hybio Pharmaceutical (SZSE:300199) Is Carrying A Fair Bit Of Debt
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Investors Push Hybio Pharmaceutical (SZSE:300199) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
hybio pharmaceutical (300199.SZ): On October 30th, Liraglutide injection ushered in a large-scale shipment with a total value of 0.103 billion yuan.
Gelonghui November 4th丨hybio pharmaceutical (300199.SZ) stated on the investor interaction platform that on October 30th, the company's Lirarutide Injection received a large-scale delivery, with a total value of 0.103 billion yuan, which was a commercial batch order announced by the company on November 3, 2023. In the future, the company will maintain a long-term exclusive cooperation relationship with Hikma according to the agreement, continue to advance subsequent order deliveries based on the sales market demand in the USA, and receive double-digit sales profit sharing. In addition to this order, the company will gradually issue subsequent orders based on the project progress. Please stay tuned for future order fulfillment.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
